ATE320259T1 - Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen - Google Patents

Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen

Info

Publication number
ATE320259T1
ATE320259T1 AT02738950T AT02738950T ATE320259T1 AT E320259 T1 ATE320259 T1 AT E320259T1 AT 02738950 T AT02738950 T AT 02738950T AT 02738950 T AT02738950 T AT 02738950T AT E320259 T1 ATE320259 T1 AT E320259T1
Authority
AT
Austria
Prior art keywords
progestogen
formula
estrogenic component
progestin
group
Prior art date
Application number
AT02738950T
Other languages
English (en)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Ti Coelingh
Christian Franz Holinka
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE320259T1 publication Critical patent/ATE320259T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02738950T 2001-05-18 2002-05-17 Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen ATE320259T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01201896A EP1260225A1 (de) 2001-05-18 2001-05-18 Pharmazeutische Zusammensetzung für die Hormonersatztherapie

Publications (1)

Publication Number Publication Date
ATE320259T1 true ATE320259T1 (de) 2006-04-15

Family

ID=8180347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738950T ATE320259T1 (de) 2001-05-18 2002-05-17 Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen

Country Status (9)

Country Link
US (1) US7723320B2 (de)
EP (3) EP1260225A1 (de)
AT (1) ATE320259T1 (de)
CA (1) CA2447175C (de)
DE (1) DE60209907T2 (de)
DK (1) DK1390039T3 (de)
ES (1) ES2260441T3 (de)
PT (1) PT1390039E (de)
WO (1) WO2002094275A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
PT1390042E (pt) 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
ATE449606T1 (de) 2001-05-23 2009-12-15 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
WO2003041718A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US7943604B2 (en) 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
US7923440B2 (en) 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
AU2003253506A1 (en) 2002-07-12 2004-02-02 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
US20060211669A1 (en) 2002-11-08 2006-09-21 Verhaar Mark T Synthesis of estetrol via estrone derived steroids
AU2004275693A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
PT1748756E (pt) * 2004-03-10 2009-07-20 Bayer Schering Pharma Ag Composições compreendendo drospirenona molecularmente dispersa
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1756139A4 (de) 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
BRPI0511079A (pt) 2004-05-11 2007-12-26 Emotional Brain Bv usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
AU2005309455A1 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
WO2007109312A2 (en) * 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
CA2674325A1 (en) 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080234243A1 (en) * 2007-01-31 2008-09-25 Lavallee Theresa M Method of treating amyloidosis mediated diseases
US8518923B2 (en) 2007-07-19 2013-08-27 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
US20100155594A1 (en) * 2008-12-23 2010-06-24 Goldman Mildred M Mass spectrometry assay for estrogenic compounds
EA025511B1 (ru) 2011-06-01 2016-12-30 Эстетра С.П.Р.Л. Способ получения промежуточных соединений эстетрола
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
JP6254289B2 (ja) 2013-09-18 2017-12-27 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． エステトロールの製造プロセス
CN103636555A (zh) * 2013-11-11 2014-03-19 徐又佳 小鼠去势高铁骨质疏松模型构建方法
NZ720906A (en) 2013-12-12 2022-04-29 Estetra Sprl Orally disintegrating solid dosage unit containing an estetrol component
EA035687B1 (ru) 2015-06-18 2020-07-27 Эстетра Спрл Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
EP3310346B1 (de) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablette enthaltend estetrol
DK3310345T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2426779A1 (de) * 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) * 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) * 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) * 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
DE60209907T2 (de) 2006-08-17
US20040186086A1 (en) 2004-09-23
ES2260441T3 (es) 2006-11-01
EP1390039A1 (de) 2004-02-25
DK1390039T3 (da) 2006-07-10
CA2447175C (en) 2010-02-16
WO2002094275A8 (en) 2003-02-13
CA2447175A1 (en) 2002-11-28
DE60209907D1 (de) 2006-05-11
PT1390039E (pt) 2006-07-31
EP1390039B1 (de) 2006-03-15
US7723320B2 (en) 2010-05-25
WO2002094275A1 (en) 2002-11-28
EP1700602A1 (de) 2006-09-13
EP1260225A1 (de) 2002-11-27

Similar Documents

Publication Publication Date Title
ATE320259T1 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
ATE350041T1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
CA2467222A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE268183T1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MY130668A (en) Isothiazole derivatives useful as anticancer agents
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
KR930003912A (ko) 울혈성 심장 마비 치료법
YU2703A (sh) Bistar vodeni anestetski preparat
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
KR880012633A (ko) C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물
CA2448278A1 (en) Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
AU2003274946A1 (en) Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
KR920000323A (ko) 재흡수성이 향상된 소마토스타틴 약학적 조성물, 그것의 제법 및 용도
GB9209882D0 (en) Compositions
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
KR950701909A (ko) 신규한 비타민D 동족체(Novel vitamin D analogues)
IL156811A0 (en) Bisaryl derivatives and pharmaceutical compositions containing the same
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
KR930019683A (ko) 사이클릭 아미노메틸렌 비스포스포네이트 유도체
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
BR0014447A (pt) Derivados de piperidina como inibidores da reabsorção
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390039

Country of ref document: EP

REN Ceased due to non-payment of the annual fee